Apnimed is a clinical-stage pharmaceutical company developing pharmacologic treatments for obstructive sleep apnea (OSA) and other sleep-related breathing disorders. Lead candidate AD109 (Oxnimbi) is a once-nightly oral combination (atomoxetine + aroxybutynin) that targets the underlying cause of upper airway collapse. Apnimed reported two Phase 3 wins in 2025 and has filed for FDA approval.
Company Info
Funding & Investor Relations
TBD
Recent News
/PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral...
Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision. The therapy, called Oxnimbi or AD109, is a drug combination that targets a cause of upper airway collapse in people with OSA. Apnimed reported two phase 3 wins for AD109 in 2025 and submitted an approval application to the FDA in April this year.
Leadership Team
CEO
Careers & Job Openings